Ebola is a severe and often fatal virus that causes hemorrhagic fever in humans and other primates. It was first identified in 1976 in Sudan and the Democratic Republic of Congo. Since then, there have been several outbreaks of Ebola, including a major epidemic in West Africa in 2014-2016 that claimed over 11,000 lives. One of the most effective ways to prevent the spread of Ebola is through vaccination. There are currently two approved Ebola vaccines: rVSV-ZEBOV and Ad26.ZEBOV/MVA-BN-Filo.
Both Ebola Vaccine have been shown to be highly effective in clinical trials and are being used to control outbreaks in Africa. rVSV-ZEBOV is a live-attenuated vaccine that uses a weakened form of the vesicular stomatitis virus (VSV) to deliver a gene for the Ebola virus glycoprotein into cells. The vaccine stimulates an immune response that protects against the Ebola virus. In clinical trials, rVSV-ZEBOV was shown to be highly effective, with a 100% efficacy rate in a trial in Guinea during the 2014-2016 outbreak.
